Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

NCT04521686 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04521686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04521686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 1, 2020
Completion date
May 31, 2027
Enrollment
200 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

any solid tumor, cholangiocarcinoma, chondrosarcoma, glioma